Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3899/jrheum.210931.C1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Overall hemostatic potential as a marker of subclinical hypercoagulability in treated psoriasis patients.
Front Med (Lausanne)
August 2025
Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
Background: Psoriasis is associated with increased cardiovascular risk, possibly mediated by inflammation-induced hemostatic dysregulation and hypercoagulability. However, these changes are often difficult to detect with conventional markers.
Objectives: To assess hypercoagulability in patients with psoriasis using the Overall Hemostatic Potential (OHP) test, a global integrative test for coagulation and fibrinolysis.
The role of the coagulation-fibrinolysis system in airway and lung remodeling.
Respir Investig
August 2025
Department of Pulmonary and Critical Care Medicine, Faculty and Graduate School of Medicine, Mie University, Japan; Department of Immunology, Faculty and Graduate School of Medicine, Mie University, Edobashi 2-174, Tsu, Mie, 514-8507, Japan.
The coagulation and fibrinolytic systems are distinct biological processes yet intricately interconnected through various regulatory mechanisms. The coagulation cascade not only serves to prevent blood loss from damaged vessels but also acts as a defense mechanism against invading pathogens and initiates vascular repair. This physiological response culminates in the formation of a fibrin mesh through a well-orchestrated cascade of enzymatic reactions.
View Article and Find Full Text PDFObesity is a major health issue and a risk factor for venous thromboembolic disease (VTE). Plasminogen activator inhibitor 1 (PAI-1), encoded by the gene SERPINE1, is a negative regulator of fibrinolysis and has been associated with obesity. The liver, which senses obesity-induced metabolic stress, is a key determinant of circulating PAI-1 levels.
View Article and Find Full Text PDFThe thrombotic paradox in congenital fibrinogen deficiencies: from pathophysiology to practice.
Res Pract Thromb Haemost
July 2025
Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.
Congenital fibrinogen deficiencies (CFDs) comprise rare inherited disorders characterized by quantitative (afibrinogenemia, hypofibrinogenemia) or qualitative (dysfibrinogenemia, hypodysfibrinogenemia) abnormalities of fibrinogen. While CFDs are typically associated with bleeding, a paradoxical risk of both arterial and venous thrombosis is being increasingly recognized. Proposed mechanisms include impaired thrombin clearance due to a lack of fibrin formation and structurally abnormal fibrin clots that promote thrombin release into the circulation or hinder fibrinolysis.
View Article and Find Full Text PDFPathogenesis, Diagnosis, and Management of Chronic Thromboembolic Pulmonary Hypertension.
Card Electrophysiol Clin
September 2025
Division of Cardiology, Department of Medicine, Emory University School of Medicine, 1364 Clifton Road Northeast Suite F606, Atlanta, GA 30322, USA. Electronic address:
Chronic thromboembolic pulmonary hypertension (CTEPH) is thought to occur as a sequelae of thromboembolic processes in the pulmonary vasculature. The pathophysiology of CTEPH is multifactorial, including impaired fibrinolysis, endothelial dysregulation, and hypoxic adaptations. The diagnosis of CTEPH is typically delayed considering the nonspecific nature of the symptoms, lack of screening, and relatively low incidence.
View Article and Find Full Text PDF